About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Gisela Nogales-Gadea is a senior biomedical researcher and group leader at the Badalona Neuromuscular Research Group (GRENBA), part of IGTP.
The DM1-Hub project has created a scientific network in Spain to study the natural history of myotonic dystrophy type 1 (DM1) and aims to identify genomic and proteomic biomarkers for personalized medicine. DM1 is a rare neuromuscular disease with no current treatment and high clinical variability. The project involves more than 100 healthcare professionals collecting lifestyle, clinical, and neuropsychological data from 3,000 patients, along with genomic and proteomic analyses of blood samples. These data will help predict disease severity, organ involvement, stratify patients for clinical trials, and identify new therapeutic targets. DM1-Hub aims to transform patient follow-up protocols, improving quality of life and life expectancy.
Host: Dr. Ramon Martí- Dr. Tomàs Pinós. Neuromuscular and Mitochondrial Pathology -Vall d'Hebron Research Institute (VHIR).
Online: https://gencat.zoom.us/j/83490766597
